12/1
10:24 am
ogn
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Low
Report
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
11/25
07:30 am
ogn
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
11/17
09:06 am
ogn
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Low
Report
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
11/17
05:30 am
ogn
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Low
Report
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
11/14
06:36 pm
ogn
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
Low
Report
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
11/11
01:11 pm
ogn
Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends [Yahoo! Finance]
Low
Report
Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends [Yahoo! Finance]
11/11
11:20 am
ogn
Organon & Co. (NYSE:OGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $14.00 to $12.00. They now have an "underweight" rating on the stock.
Low
Report
Organon & Co. (NYSE:OGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $14.00 to $12.00. They now have an "underweight" rating on the stock.
11/11
08:09 am
ogn
Organon & Co. (NYSE:OGN) had its price target lowered by analysts at Morgan Stanley from $10.00 to $9.00. They now have an "equal weight" rating on the stock.
Low
Report
Organon & Co. (NYSE:OGN) had its price target lowered by analysts at Morgan Stanley from $10.00 to $9.00. They now have an "equal weight" rating on the stock.
11/10
04:32 pm
ogn
Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... [Yahoo! Finance]
Medium
Report
Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... [Yahoo! Finance]
11/10
07:30 am
ogn
Organon Reports Results for the Third Quarter Ended September 30, 2025
High
Report
Organon Reports Results for the Third Quarter Ended September 30, 2025
11/8
08:00 am
ogn
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
High
Report
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
11/7
07:30 am
ogn
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
Low
Report
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
11/6
07:30 am
ogn
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
Medium
Report
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
10/28
01:04 pm
ogn
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
Low
Report
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
10/27
06:22 pm
ogn
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman
Medium
Report
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman
10/27
12:08 pm
ogn
Organon & Co. (NYSE:OGN) was downgraded by analysts at Piper Sandler from an "overweight" rating to an "underweight" rating. They now have a $5.00 price target on the stock.
Low
Report
Organon & Co. (NYSE:OGN) was downgraded by analysts at Piper Sandler from an "overweight" rating to an "underweight" rating. They now have a $5.00 price target on the stock.
10/27
07:30 am
ogn
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
High
Report
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
10/16
07:52 pm
ogn
Organon (OGN) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]
Low
Report
Organon (OGN) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]
10/7
05:39 pm
ogn
AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight [Yahoo! Finance]
Low
Report
AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight [Yahoo! Finance]
10/6
08:02 pm
ogn
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]
Low
Report
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]
10/6
10:47 am
ogn
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings [Yahoo! Finance]
Low
Report
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings [Yahoo! Finance]
9/29
07:15 pm
ogn
Organon (OGN) Outperforms Broader Market: What You Need to Know [Yahoo! Finance]
Medium
Report
Organon (OGN) Outperforms Broader Market: What You Need to Know [Yahoo! Finance]
9/19
07:59 am
ogn
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
Medium
Report
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
9/19
06:00 am
ogn
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
Medium
Report
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
9/12
05:40 pm
ogn
Is Biogen Stock Underperforming the Nasdaq? [Yahoo! Finance]
Low
Report
Is Biogen Stock Underperforming the Nasdaq? [Yahoo! Finance]